BioHealth Innovation, Inc. (BHI), a public-private partnership and innovation intermediary is seeking an energetic and motivated life science professional for the role of an Entrepreneur-In-Residence (EIR) preferably with product development experience related to cardiovascular, pulmonary, or hematological innovations. The EIR will reside within the National Institutes of Health (NIH) and will also support intramural and extramural initiatives on an as needed basis.
The EIR program was established at BioHealth Innovation to:
Retain and bring entrepreneurial talent to the Maryland ecosystem
Connect resources including institutions, technology assets, people and capital within Maryland that include federal institutions, labs, academic institutions, small businesses, disease foundations and the investor community
Build/support sustainable life science startups that will add value within the healthcare system and also build upon the existing infrastructure
The EIR will work with BHI leadership to ensure that the activities and outcomes are aligned with BHIs strategic focus.
The Information Technology (IT) Manager will develop, assess and maintain secure, effective and innovative information technology functions at BHI. The IT Manager influences the BHI organization by strategically managing and providing information, intelligence and insights which influence BHI operations decisions and promote the image of the organization.
Whatever Johnson & Johnson ($JNJ) learned about MacroGenics’ off-the-shelf approach to stirring a T cell attack against cancer since inking their first partnership deal 17 months ago seems to have only whetted the pharma giant’s appetite for more.
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that it has entered into a definitive agreement to sell 2,700,000 shares of its common stock and warrants to purchase 2,700,000 shares of common stock in a private placement. The securities are being sold in a private offering at a price of $0.40 per one share of common stock and one common stock purchase warrant. The warrants have an exercise price of $0.40 per share, are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.
At the North Bethesda Marriott, Maryland’s leading technology and life science companies gathered to celebrate recent successes from the most innovative teams in the state on Thursday night’s industry celebration.
Roche Venture Fund and 5AM Ventures have led Purigen Biosystems to an $18.2 million Series A round. Purigen will use the money to advance the development and commercialization of a benchtop system for extracting, quantifying and enriching of samples for genomic testing.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of the offer period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN had published a conditional, voluntary public tender offer for the shares in Exiqon, in which the shareholders of Exiqon were offered a cash amount of DKK 18 for each share they held in Exiqon. In accordance with the Offer, the Offer Period expired yesterday on 18 May 2016 at 23.59 (CET).
Roche Holding (RHHBY – Analyst Report) announced that the FDA has granted accelerated approval to its cancer immunotherapy drug, Tecentriq (atezolizumab), for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma (mUC), who experienced disease progression during or after platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.
Extending their partnership to an eighth company, La Jolla’s Avalon Ventures and UK-based drug giant GSK said Friday they have formed another San Diego biotech startup.
Johns Hopkins University President Ronald J. Daniels was among the speakers Thursday at the fifth annual U.S. News & World Report STEM Solutions National Leadership Conference in Baltimore.
The three-day conference brought together leaders from academia, business, and government to contribute key insights into science, technology, engineering, and mathematics—or STEM—education. The summit focused on solutions and best practices to ensure that the nation’s future workforce has the necessary skills and knowledge to thrive in a global economy.
TEDCO handed out its annual honors for “Innovation,” “Corporate Excellence” and “Entrepreneurship” on Tuesday. The ICE Awards ceremony at Columbus Center in Inner Harbor marked a move into Baltimore city after last year’s event in Columbia.
Kevin Plank encourages University of Maryland graduates to let “passion” fuel their dreams Kevin Plank remembers sitting in his cap and gown at the University of Maryland, College Park commencement ceremony in 1996 as Hillary Clinton spoke to his graduating class. He also remembers that he was fidgeting in his seat and only half-listening.
The National Human Genome Research Institute of the National Institutes of Health (NIH) has awarded the Johns Hopkins Berman Institute of Bioethics a “Center of Excellence” grant to study the ethical, legal and social implications (ELSI) of applying genomics to research on, and the prevention and treatment of, infectious disease. This builds on three years of work of an exploratory Center of Excellence in ELSI Research (CEER) at the Berman Institute, the first such project to focus attention on genomic ELSI issues in the context of infectious disease.
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced approval of the VENTANA PD-L1 (SP142) Assay1 by the US Food and Drug Administration (FDA) as a complementary diagnostic to provide PD-L1 status on patients who are considering treatment with the FDA approved Roche immunotherapy TECENTRIQ™ (atezolizumab) for metastatic urothelial cancer (mUC). This test is the first to evaluate patient PD-L1 status using immune cell staining and scoring within the tumor microenvironment, providing clinicians with information that may guide immunotherapy decisions2.
Novartis is splitting its pharmaceuticals division into two business units, one focused on cancer and the second on other drugs, while switching out its current pharma head in the second high-profile management reshuffle this year.
Dr. J. Thomas August, who has spent the last 40 years at Johns Hopkins and decades developing a way for people to fight off viruses, has turned his attention to developing a Zika virus vaccine. He is relying upon one of his own discoveries – a means of delivering cells injected with the DNA code of the virus to a person’s own immune system to fight off infection. “Others talk about 10 years to invent and develop a new vaccine,” said August, “We’re going to do this in about a year.” August is bankrolling his new Baltimore-based company called Pharos Biologicals with his own money and has enlisted CEO David Wise to help raise as much as $5 million to conduct the initial trials.
Researchers at the University of Maryland were able pull away color and chemicals from a block of wood to leave it impressively see-through. The result is a material that is both stronger and more insulating than glass, with better biodegradability than plastic. “We were very surprised by how transparent it could go,” said Liangbing Hu, who wrote about the project in Advanced Materials.
Sanofi Genzyme, the specialty care global business unit of Sanofi (NYSE: SNY), announced today a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to inform new therapeutic approaches to treating disease progression.
Satellite campuses are increasingly popular for public institutions hoping to expand their reach and increase access to students throughout the state, but the Post reports Maryland’s configuration of combining nine satellite programs onto one campus is unique.
The 2030 Group has hired a consultant to create a campaign to rebrand Greater Washington and expects to launch that campaign early next year. The fear is that the region all too often loses its best and brightest to places such as Silicon Valley and lags when it comes to diversifying its economy away from a dependence on the federal government to a more entrepreneurial one centered on innovation.
The state venture capital fund led an add-on investment for Columbia’s Healthcare Interactive and is the kind of deal the fund wants to do more of in the future.
It’s abundantly clear that microörganisms play an essential role in maintaining the health of humans, animals, and plants. But how exactly they pull this off is still mostly a mystery—one that the White House hopes to help solve by way of a new microbiome research initiative.
Decades of research have linked specific personality traits to a longer life expectancy. Some of them — from friendliness to emotional stability — may be written into our genes.
And while one study found that we’re not particularly good at identifying these traits in ourselves, it suggested that our close friends are often spot-on.
What 4000+ corporate directors think about the economy, risk, board strengths and weaknesses, and boardroom diversity
“Boards cannot afford to have directors around the table who aren’t delivering value,” says a new report based on the 2016 Global Board of Directors Survey, released from Professor Boris Groysberg and Yo-Jud Cheng of Harvard Business School, Spencer Stuart, the WomenCorporateDirectors (WCD) Foundation, and researcher Deborah Bell. With greater institutional and activist shareholder activity and stronger concerns about risk and global competitive threats, boards are taking on “a more strategic, dynamic, and responsive role” in their companies, the report states – pushing “issues around board composition and diversity to the fore.”
It will be obvious when the Department of Health and Human Services’ IDEA Lab is a success, because it will no longer be needed, according to Damon Davis, the director of the department’s Health Data Initiative.
The TMCx accelerator program couples the resources of Texas Medical Center with the innovative horsepower of entrepreneurs working in the areas of medical technology and digital health. Throughout the program, startups engage with TMC physicians and other hospital stakeholders to refine their value proposition and determine their product/market fit.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.